⌕
Amylyx Pharmaceuticals · AMLX · Nasdaq
Tenet 57 · Mixed
Compare
$30.29+1.44%At closeTenet 57 · Mixed
$30.29+0.43 (+1.44%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Amylyx Pharmaceuticals (AMLX) Stock

Amylyx Pharmaceuticals (AMLX) closed at $30.29 on Nov 13, 2026; its Tenet Score is 57 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

28 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$30.29
Nov 13, 2026
Market cap
$3.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
10.83 – 41.14
low → high
Tenet Score
57/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Amylyx Pharmaceuticals Inc scores 57/100. Mixed. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 57 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
57/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
40
Quality
34
Health
97
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityDHealthA+Growth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
5.2×
price to book value
P/S
—
no P/S on file
ROE
−30%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
pre_revenue
Current ratio
26.81
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 70 US ETFs · top wrappers by weightSee all ETFs holding AMLX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Amylyx Pharmaceuticals' Tenet Score?

Amylyx Pharmaceuticals' Tenet Score is 57 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.